Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart

Cardiovascular Drugs and Therapy

Volumn 29, Issue 3, 2015, Pages 243-255

  Zhang, Li Hui ^a   Pang, Xue Fen ^a   Bai, Feng ^a   Wang, Ning Ping ^b   Shah, Ahmed Ijaz ^b   McKallip, Robert J ^b   Li, Xue Wen ^a   Wang, Xiong ^a   Zhao, Zhi Qing ^a,b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ACE2; Angiotensin II receptors; Cardiac fibrosis; Collagen; Dipeptidyl peptidase 4; Glucagon like peptide 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LINAGLIPTIN; LIRAGLUTIDE; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCAGON LIKE PEPTIDE 1; SMAD PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG STABILITY; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; HEART; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MYOFIBROBLAST; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR DOWN REGULATION; UPREGULATION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CARDIAC MUSCLE; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENE EXPRESSION; METABOLISM; PATHOLOGY;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; COLLAGEN; FIBROSIS; GENE EXPRESSION; GLUCAGON-LIKE PEPTIDE 1; LINAGLIPTIN; LIRAGLUTIDE; MALE; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84938415449     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6592-7     Document Type: Article

References (44)

1. Liehn EA, Postea O, Curaj A, Marx N. Repair after myocardial infarction between fantasy and reality. J Am Coll Cardiol. 2011;58:2357–62.
2. Weber KT. Fibrosis in hypertension heart disease: focus on cardiac fibroblasts. J Hypertens. 2004;22:47–60.
3. Crowley MJ, Powers BJ, Myers ER, McBroom AJ, Sanders G. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: future research needs prioritization. Am Heart J. 2012;163:777–82.
4. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther. 2008;120:292–316.
5. Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT2 receptor and tissue injury: therapeutic implications. Curr Hypertens Res. 2014;16:416–26.
6. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2:247–57.
7. Ram CVS. Angiotensin receptor blockers: current status and future prospects. Am J Med. 2008;121:656–63.
8. Anavekar NS, Solomon SD. Angiotensin II receptor blockade and ventricular remodeling. JRAAS. 2005;6:43–8.
9. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492–9.
10. Pabreja K, Mohd MA, Kode C, Wootten D, Furness SGB. Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. Br J Pharmacol. 2014;171:1114–28.
11. Hausenloy DJ, Whitington HJ, Wynne AM, Begum SS, Theodorou L, Riksen N, et al. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol. 2013;22:154.
12. Johansen OE, Neubache D, Eynatten MV, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified prospective, and adjudicated mata-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3–13.
13. Wang XM, Yang YJ, Wu YJ. The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives. Cardiovasc Drugs Ther. 2013;27:297–307.
14. Knudsen LB. Liraglutide: the therapeutic promise from animal models. Int J Clin Pract. 2010;64:4–11.
15. Kern M, Kioting N, Niessen HG, Thomas L, Stiller D, Mark M, et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One. 2012;7:e38744.
16. Wang NP, Wang ZF, Tootle S, Philip TJ, Zhao ZQ. Curcumin promotes cardiac repair and ameliorates cardiac dysfunction following myocardial infarction. Br J Pharmacol. 2012;167:1550–62.
17. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang K, et al. Hydrolysis of biological peptide by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838–43.
18. Clarke SJ, McCormick LM, Dutka DP. Optimizing cardioprotection during myocardial ischemia: targeting potential intracellular pathways with glucagon-like peptide-1. Cardiovasc Diabetol. 2014;13:12–22.
19. Dai Y, Mehta JL, Chen M. Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 endothelial cell by repressing nuclear factor-kappa B activation. Cardiovasc Drugs Ther. 2013;27:371–80.
20. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al. GLP-1 receptor agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975–83.
21. Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther. 2007;21:253–6.
22. Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res. 2012;94:316–23.
23. Jones ES, Black MJ, Widdop RE. Angiotensin AT2 receptor contributes to cardiovascular remodeling of aged rats during chronic AT1 receptor blockade. J Mol Cell Cardiol. 2004;37:1023–30.
24. Yuan SM, Jing H. Cardiac pathologies in relation to Smad-dependent pathways. Interact Cardiovasc Thorac Surg. 2010;11:455–60.
25. Euler-Taimor G, Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res. 2006;69:15–25.
26. Bujak M, Frangogiannis NG. The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 2007;74:184–95.
27. Wang B, Omara A, Angelovska T, Drobic V, Rattan SG, Jones SC, et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Physiol Heart Circ Physiol. 2007;293:H1282–90.
28. Hao JM, Wang BQ, Jones SC, Jassal DS, Dixon IMC. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Am J Physiol Heart Circ Physiol. 2000;279:H3020–30.
29. Iwasaki T, Mukasa K, Yoneda M, Ito S, Yamada Y, Mori Y, et al. A marked attenuation of production of collagen type I from cardiac fibroblasts by dehydroepiandrosterone. Am J Physiol Endocrinol Metab. 2005;288:E1222–8.
30. Gao XR, He XY, Luo B, Peng LY, Lin J, Zuo ZY. Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts. Eur J Pharmacol. 2009;606:115–20.
31. Qi GM, Jia L, Li YL, Bian Y, Cheng JZ, Li HH, et al. Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration and cardiac fibrosis are pressure dependent. Cardiovasc Toxicol. 2011;11:157–67.
32. Hocher B, Sharkovska Y, Mark M, Klein T, Pfab T. The novel DPP-4 inhibitor linagliptin and BI 14361 reduce infarct size after myocardial ischemia/reperfusion in rats. Int J Cardiol. 2013;167:87–93.
33. Dai Y, Dai D, Wang XW, Ding ZF, Mehta JL. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc Drugs Ther. 2014;28:425–32.
34. Sortino MA, Sinagra T, Canonico PL. Linagliptin: a thorough characterization beyond its clinical efficacy. Front Endocrinol. 2013;4:1–9.
35. Keidar S, Kaplan M, Gamliel -Lazarovich A. ACE2 of the heart: from angiotensin I to angiotensin (1-7). Cardiovasc Res. 2007;73:463–9.
36. Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M, et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension. 2006;47:718–26.
37. Benter IF, Yousif MHM, Cojocel C, AI-Maghrebi M, Diz DI. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol. 2007;292:H666–72.
38. Patel VB, Bodiga S, Fan D, Das SK, Wang ZH, Wang W, et al. Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2 - null mice. Hypertension. 2012;59:1195–203.
39. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007;292:H736–42.
40. Pyke C, Heller S, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–90.
41. Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289:H2401–8.
42. Hanafy H, Tavasoli M, Jamali F. Inflammation alters angiotensin converting enzymes (ACE and ACE-2) balance in rat heart. Inflammation. 2011;34:609–13.
43. Klein T, Fuji M, Sandel J, Shibazaki Y, Wakamatsu K, Mark M, et al. Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med Mol Morphol. 2014;47:137–49.
44. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A, et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol. 2010;9:76–90.